Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 345 publications
Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 07, 2026
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 14, 2026
Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).
Journal: AJNR. American journal of neuroradiology
Published: February 19, 2026
Clinical and radiographic prognostic factors in recurrent contrast-enhancing IDH-mutant gliomas treated with bevacizumab.
Journal: Neuro-oncology advances
Published: December 29, 2025
Influence of post-bolus acquisition duration on estimated percentage of signal recovery from dynamic susceptibility contrast MRI in brain tumors.
Journal: AJNR. American journal of neuroradiology
Published: December 01, 2025
Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 18, 2025
MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.
Journal: Journal of neuro-oncology
Published: November 01, 2025
Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.
Journal: Neuro-oncology advances
Published: October 27, 2025
A multifocal IDH-mutant glioma with differential response to IDH inhibition: Role of quantitative neuroimaging.
Journal: Radiology case reports
Published: October 27, 2025
Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas.
Journal: Neuro-oncology
Published: September 01, 2025
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Journal: Neuro-oncology
Published: August 19, 2025
Last Updated: 09/26/2026